Clinical and endocrine effects of cyproterone acetate in postmenopausal patients with advanced breast cancer

European Journal of Cancer and Clinical Oncology

Volumn 24, Issue 3, 1988, Pages 417-421

  Willemse, P H B ^a   Dikkeschei, L D ^b   Mulder, N H ^a   Van Der Ploeg, E ^a   Sleijfer, D TH ^a   De Vries, E G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE;

ADULT; AGED; BREAST CANCER; CLINICAL ARTICLE; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYPROTERONE; CYPROTERONE ACETATE; DEHYDROEPIANDROSTERONE SULFATE; DRUG EVALUATION; FEMALE; FOLLICLE STIMULATING HORMONE; HEPATITIS, TOXIC; HUMAN; LUTEINIZING HORMONE; MIDDLE AGE; PRASTERONE;

EID: 0023902246     PISSN: 02775379     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0277-5379(98)90011-6     Document Type: Article

References (24)

1. High-dose medroxyprogesterone acetate treatment in advanced mammary carcinoma
2. A possible new approach of the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate
3. High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer
4. Oral high-dose medroxyprogesterone acetate versus tamoxifen
5. Behandlung des Hirsutismus mit Cyproteronacetat
6. Experience in the treatment of prostatic cancer with CPA
7. Cyproteroneacetate and ACTH adrenal function
8. Cyproterone acetate
9. Cyproterone acetate in the treatment of metastatic cancer of the male breast
10. Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects
11. Progesterone oral contraception and blood coagulation
12. Cardiovascular side-effects under medroxyprogesterone acetate treatment
13. Thromboembolic disease in breast cancer patients receiving chemo/hormonal therapy
14. Hepatocellular damage by cyproterone acetate
15. Pharmacokinetic consequences of aging
16. Age-related changes in drug disposition
17. 3H after oral administration as a coated tablet (SH B 209 AB)
18. ®) to five young women
19. Effects of cyproterone and cyproterone acetate on the biosynthesis of steroidal hormones
20. Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients
21. Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women
22. Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients